Steven Novick
About
Steven Novick is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Steven Novick has authored 28 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 10 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Steven Novick's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Steven Novick is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Steven Novick collaborates with scholars based in United States, Switzerland and Germany. Steven Novick's co-authors include Steven L. Soignet, Stephanie Stahl, Beverly S. Mitchell, Mary Jo Lehman, Roberto Guerciolini, Jessica Anderson, Thomas C. Shea, Julian Adams, Thomas E. Stinchcombe and Dixie‐Lee Esseltine and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.
In The Last Decade
Steven Novick
27 papers receiving 1.4k citations
Hit Papers
Peers
Steven Novick
Miyuki Akutsu Japan
Chetasi Talati United States
Halyna Pylypenko Czechia
Kathy Chun Canada
Norma E. Fox United States
Z Estrov United States
Kevin Yee United States
Francesco Turturro United States
Dixie‐Lee Esseltine United States
Joseph M. Gozgit United States
Citations per year, relative to Steven Novick Steven Novick (= 1×)
peers
Miyuki Akutsu
Countries citing papers authored by Steven Novick
Since
Specialization
Citations
This map shows the geographic impact of Steven Novick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Novick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Novick more than expected).
Fields of papers citing papers by Steven Novick
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Steven Novick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Novick. The network helps show where Steven Novick may publish in the future.
Co-authorship network of co-authors of Steven Novick
This figure shows the co-authorship network connecting the top 25 collaborators of Steven Novick. A scholar is included among the top collaborators of Steven Novick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Novick. Steven Novick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shepard, Dale R., Patricia LoRusso, Leonard J. Appleman, et al.. (2024). Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3027–3027.
2.
Usmani, Saad Z., Jesús G. Berdeja, Anna Truppel-Hartmann, et al.. (2020). KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma. Blood. 136(Supplement 1). 18–19.
3.
Delforge, Michel, Rachid Baz, Michèle Cavo, et al.. (2020). KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma. Blood. 136(Supplement 1). 24–25.
4.
Hochhaus, Andreas, Michele Baccarani, Francis J. Giles, et al.. (2015). Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. Journal of Cancer Research and Clinical Oncology. 141(11). 2047–2060.
5.
Blay, Jean‐Yves, Lin Shen, Yoon‐Koo Kang, et al.. (2015). Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. The Lancet Oncology. 16(5). 550–560.
6.
Zhang, Hefei, et al.. (2014). Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. The Journal of Clinical Pharmacology. 55(4). 401–408.
7.
Hochhaus, Andreas, Philipp D. le Coutre, Hagop M. Kantarjian, et al.. (2013). Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. Journal of Cancer Research and Clinical Oncology. 139(12). 1985–1993.
8.
Blay, Jean‐Yves, Lin Shen, Yoon‐Koo Kang, et al.. (2013). Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 31(15_suppl). 10501–10501.
9.
Giles, Francis J., Philipp D. le Coutre, Javier Pinilla‐Ibarz, et al.. (2012). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27(1). 107–112.
10.
Yin, Ophelia, Véronique Bédoucha, Tracey McCulloch, et al.. (2012). Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemotherapy and Pharmacology. 71(1). 219–226.
11.
Coutre, Philipp D. le, Francis J. Giles, Javier Pinilla‐Ibarz, et al.. (2011). Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. Blood. 118(21). 3770–3770.
12.
Moore, Johnnie N., et al.. (2008). Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study. Journal of Clinical Oncology. 26(15_suppl). 7008–7008.
13.
Julian, Thomas B., et al.. (2007). Phase 1 Assessment of an Orally Bioavailable Formulation of Gallium Nitrate (G4544).. Blood. 110(11). 4455–4455.
14.
Marcucci, Guido, Wendy Stock, Guowei Dai, et al.. (2005). Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. Journal of Clinical Oncology. 23(15). 3404–3411.
15.
Mavromatis, Blanche H., R. Kanti, Paul K. Wallace, et al.. (2005). Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.. Blood. 106(11). 2129–2129.
16.
O’Brien, Susan, et al.. (2005). Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 23(30). 7697–7702.
17.
Wieder, Robert, Steven Novick, Bruce W. Hollis, et al.. (2003). Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Investigational New Drugs. 21(4). 445–452.
18.
Tippin, Timothy K., Geraldine A. Hamilton, Linda B. Moore, et al.. (2003). CYP3A INDUCTION BY N-HYDROXYFORMAMIDE TUMOR NECROSIS FACTOR-α CONVERTING ENZYME/MATRIX METALLOPROTEINASE INHIBITORS: USE OF A PREGNANE X RECEPTOR ACTIVATION ASSAY AND PRIMARY HEPATOCYTE CULTURE FOR ASSESSING INDUCTION POTENTIAL IN HUMANS. Drug Metabolism and Disposition. 31(7). 870–877.
19.
Orlowski, Robert Z., Thomas E. Stinchcombe, Beverly S. Mitchell, et al.. (2002). Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies. Journal of Clinical Oncology. 20(22). 4420–4427.
20.
D’Adamo, David R., et al.. (1997). rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene. 14(11). 1295–1305.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Miyuki Akutsu Breakdown of academic impact, for papers by Chetasi Talati Breakdown of academic impact, for papers by Halyna Pylypenko Breakdown of academic impact, for papers by Kathy Chun Breakdown of academic impact, for papers by Norma E. Fox Breakdown of academic impact, for papers by Z Estrov Breakdown of academic impact, for papers by Kevin Yee Breakdown of academic impact, for papers by Francesco Turturro Breakdown of academic impact, for papers by Dixie‐Lee Esseltine Breakdown of academic impact, for papers by Joseph M. Gozgit